SMPDL3B and acute myeloid leukemia: Consistent with these results, the overall survival rates were significantly different between SMPDL3B low and SMPDL3B high AML patients in preplanned age <60, age ≥60, cytogenetics risk favorable, cytogenetics intermediate, and IDH1 negative subgroups (Figures 3A–D,G).